357 related articles for article (PubMed ID: 33284994)
1. Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma.
Arlt B; Zasada C; Baum K; Wuenschel J; Mastrobuoni G; Lodrini M; Astrahantseff K; Winkler A; Schulte JH; Finkler S; Forbes M; Hundsdoerfer P; Guergen D; Hoffmann J; Wolf J; Eggert A; Kempa S; Deubzer HE
Int J Cancer; 2021 Mar; 148(5):1219-1232. PubMed ID: 33284994
[TBL] [Abstract][Full Text] [Related]
2. Venetoclax-based Rational Combinations are Effective in Models of
Dalton KM; Krytska K; Lochmann TL; Sano R; Casey C; D'Aulerio A; Khan QA; Crowther GS; Coon C; Cai J; Jacob S; Kurupi R; Hu B; Dozmorov M; Greninger P; Souers AJ; Benes CH; Mossé YP; Faber AC
Mol Cancer Ther; 2021 Aug; 20(8):1400-1411. PubMed ID: 34088831
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Phosphoglycerate Dehydrogenase Attenuates Bleomycin-induced Pulmonary Fibrosis.
Hamanaka RB; Nigdelioglu R; Meliton AY; Tian Y; Witt LJ; O'Leary E; Sun KA; Woods PS; Wu D; Ansbro B; Ard S; Rohde JM; Dulin NO; Guzy RD; Mutlu GM
Am J Respir Cell Mol Biol; 2018 May; 58(5):585-593. PubMed ID: 29019702
[TBL] [Abstract][Full Text] [Related]
4. Glycine decarboxylase is a transcriptional target of MYCN required for neuroblastoma cell proliferation and tumorigenicity.
Alptekin A; Ye B; Yu Y; Poole CJ; van Riggelen J; Zha Y; Ding HF
Oncogene; 2019 Dec; 38(50):7504-7520. PubMed ID: 31444411
[TBL] [Abstract][Full Text] [Related]
5. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.
Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC
Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377
[TBL] [Abstract][Full Text] [Related]
6. Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition.
Ngo B; Kim E; Osorio-Vasquez V; Doll S; Bustraan S; Liang RJ; Luengo A; Davidson SM; Ali A; Ferraro GB; Fischer GM; Eskandari R; Kang DS; Ni J; Plasger A; Rajasekhar VK; Kastenhuber ER; Bacha S; Sriram RK; Stein BD; Bakhoum SF; Snuderl M; Cotzia P; Healey JH; Mainolfi N; Suri V; Friedman A; Manfredi M; Sabatini DM; Jones DR; Yu M; Zhao JJ; Jain RK; Keshari KR; Davies MA; Vander Heiden MG; Hernando E; Mann M; Cantley LC; Pacold ME
Cancer Discov; 2020 Sep; 10(9):1352-1373. PubMed ID: 32571778
[TBL] [Abstract][Full Text] [Related]
7. Catastrophic ATP loss underlies a metabolic combination therapy tailored for
Dalton KM; Lochmann TL; Floros KV; Calbert ML; Kurupi R; Stein GT; McClanaghan J; Murchie E; Egan RK; Greninger P; Dozmorov M; Ramamoorthy S; Puchalapalli M; Hu B; Shock L; Koblinski J; Glod J; Boikos SA; Benes CH; Faber AC
Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33762304
[No Abstract] [Full Text] [Related]
8. Inhibiting PHGDH with NCT-503 reroutes glucose-derived carbons into the TCA cycle, independently of its on-target effect.
Arlt B; Mastrobuoni G; Wuenschel J; Astrahantseff K; Eggert A; Kempa S; Deubzer HE
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1282-1289. PubMed ID: 34192988
[TBL] [Abstract][Full Text] [Related]
9. Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers.
Mullarky E; Lucki NC; Beheshti Zavareh R; Anglin JL; Gomes AP; Nicolay BN; Wong JC; Christen S; Takahashi H; Singh PK; Blenis J; Warren JD; Fendt SM; Asara JM; DeNicola GM; Lyssiotis CA; Lairson LL; Cantley LC
Proc Natl Acad Sci U S A; 2016 Feb; 113(7):1778-83. PubMed ID: 26831078
[TBL] [Abstract][Full Text] [Related]
10. Serine-Glycine-One-Carbon Metabolism: The Hidden Achilles Heel of
Garcia AR; Arsenian-Henriksson M
Cancer Res; 2019 Aug; 79(15):3818-3819. PubMed ID: 31371280
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[
Li C; Huang S; Guo J; Wang C; Huang Z; Huang R; Liu L; Liang S; Wang H
Mol Imaging Biol; 2019 Dec; 21(6):1117-1126. PubMed ID: 30850970
[TBL] [Abstract][Full Text] [Related]
12. Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin.
Zhang X; Bai W
Cancer Chemother Pharmacol; 2016 Sep; 78(3):655-9. PubMed ID: 27473325
[TBL] [Abstract][Full Text] [Related]
13. Thymidylate synthase inhibitor raltitrexed can induce high levels of DNA damage in MYCN-amplified neuroblastoma cells.
Yamashita K; Kiyonari S; Tsubota S; Kishida S; Sakai R; Kadomatsu K
Cancer Sci; 2020 Jul; 111(7):2431-2439. PubMed ID: 32415892
[TBL] [Abstract][Full Text] [Related]
14. A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate.
Pacold ME; Brimacombe KR; Chan SH; Rohde JM; Lewis CA; Swier LJ; Possemato R; Chen WW; Sullivan LB; Fiske BP; Cho S; Freinkman E; Birsoy K; Abu-Remaileh M; Shaul YD; Liu CM; Zhou M; Koh MJ; Chung H; Davidson SM; Luengo A; Wang AQ; Xu X; Yasgar A; Liu L; Rai G; Westover KD; Vander Heiden MG; Shen M; Gray NS; Boxer MB; Sabatini DM
Nat Chem Biol; 2016 Jun; 12(6):452-8. PubMed ID: 27110680
[TBL] [Abstract][Full Text] [Related]
15. DNA Ligase 4 Contributes to Cell Proliferation against DNA-PK Inhibition in
Ando K; Suenaga Y; Kamijo T
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240360
[TBL] [Abstract][Full Text] [Related]
16. Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E.
Ma X; Li B; Liu J; Fu Y; Luo Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):66. PubMed ID: 30744688
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.
Dolman ME; Poon E; Ebus ME; den Hartog IJ; van Noesel CJ; Jamin Y; Hallsworth A; Robinson SP; Petrie K; Sparidans RW; Kok RJ; Versteeg R; Caron HN; Chesler L; Molenaar JJ
Clin Cancer Res; 2015 Nov; 21(22):5100-9. PubMed ID: 26202950
[TBL] [Abstract][Full Text] [Related]
18. The Role of D-3-Phosphoglycerate Dehydrogenase in Cancer.
Zhao X; Fu J; Du J; Xu W
Int J Biol Sci; 2020; 16(9):1495-1506. PubMed ID: 32226297
[TBL] [Abstract][Full Text] [Related]
19. Homoharringtonine as a PHGDH inhibitor: Unraveling metabolic dependencies and developing a potent therapeutic strategy for high-risk neuroblastoma.
Hsieh CH; Huang CT; Cheng YS; Hsu CH; Hsu WM; Chung YH; Liu YL; Yang TS; Chien CY; Lee YH; Huang HC; Juan HF
Biomed Pharmacother; 2023 Oct; 166():115429. PubMed ID: 37673018
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Reprogramming by MYCN Confers Dependence on the Serine-Glycine-One-Carbon Biosynthetic Pathway.
Xia Y; Ye B; Ding J; Yu Y; Alptekin A; Thangaraju M; Prasad PD; Ding ZC; Park EJ; Choi JH; Gao B; Fiehn O; Yan C; Dong Z; Zha Y; Ding HF
Cancer Res; 2019 Aug; 79(15):3837-3850. PubMed ID: 31088832
[No Abstract] [Full Text] [Related]
[Next] [New Search]
